VX15/2503 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Huntington's Disease
Conditions
Huntington's Disease
Trial Timeline
Jul 1, 2015 → Aug 1, 2020
NCT ID
NCT02481674About VX15/2503 + Placebo
VX15/2503 + Placebo is a phase 2 stage product being developed by Vaccinex for Huntington's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02481674. Target conditions include Huntington's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02481674 | Phase 2 | Completed |
| NCT01764737 | Phase 1 | Completed |
Competing Products
15 competing products in Huntington's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 2 | 52 |
| RG6496 + Placebo | Roche | Phase 1 | 33 |
| PF-02545920 + PF-02545920 | Pfizer | Phase 2 | 51 |
| 20 mg BID of PF-02545920 | Pfizer | Phase 2 | 51 |
| PF-02545920 + Placebo + PF-02545920 + Placebo | Pfizer | Phase 2 | 51 |
| ALN-HTT02 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Tetrabenazine | Lundbeck | Approved | 82 |
| BN82451B + Placebo | Ipsen | Phase 2 | 49 |
| ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mg | Ionis Pharmaceuticals | Phase 1/2 | 38 |
| WVE-120102 + Placebo | WaVe Life Sciences | Phase 1/2 | 36 |
| WVE-120101 + Placebo | WaVe Life Sciences | Phase 1/2 | 36 |
| SAGE-718 | Supernus Pharmaceuticals | Phase 3 | 72 |
| SAGE-718 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |
| OMS643762 + Placebo | Omeros Corporation | Phase 2 | 47 |